Xinran Yuan

Xinran Yuan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
XYXinran Yuan
Xinran Yuan
XQXiaodong Qin
Xiaodong Qin
KTKenji Takemoto
Kenji Takemoto
JZJian Zhao
Jian Zhao
MSMatthew Sanderson
Matthew Sanderson
BTBetty P. Tsao
Betty P. Tsao
We assessed the role of a systemic lupus erythematosus causal hypofunctional variant, neutrophil cytosolic factor 1 (NCF1)-p.Arg90His (p.R90H) substitution, in systemic sclerosis (SSc). Association of NCF1-H90 with SSc was performed in case-control cohorts, bleomycin (BLM)-treated Ncf1-R90 C57BL/6 wildtype and Ncf1-H90 knock-in (KI) littermates. Peripheral blood mononuclear cell (PBMC) subsets were analysed by cytometry by time-of-flight. The NCF1-H90 allele is associated with risk for diffuse cutaneous SSc (dcSSc) in Chinese and European Americans, and lung fibrosis in Chinese patients with SSc (OR=2.09, p=7.96E-10). Low copy number of NCF1 associated with lung fibrosis in European Americans (OR=4.33, p=2.60E-2). BLM-treated KI mice demonstrated increased pulmonary fibrosis, exhibiting activated type I interferon signature, elevated Spp1, Ccl2, Arg1, Timp1 and Il6 expression, enriched macrophage scores in lung tissues. In a longitudinal observation cohort, homozygous H90 patients with SSc at baseline had increased anti-nuclear antibody titres, anti-topoisomerase antibody seropositivity and anti-centromere antibody seronegativity, increased incidence of lung fibrosis and Gender-Age-lung Physiology index, elevated modified Rodnan Skin Score (mRSS) and elevated plasma osteopontin (OPN, SPP1), CCL2, ARG1, TIMP-1 and IL-6. These H90 patients with SSc sustained elevated mRSS during follow-up years with decreased survival. The 0, 1 and 2 copies of H90 carriage in SSc PBMCs exhibited dose-dependent increases in profibrotic CD14+CD68+CD11b+Tim3+monocytes. Elevated OPN, CCL2 and ARG1 in CD68+CD11b+monocyte-derived macrophages from H90 patients were decreased after co-culturing with anti-CCL2 antibody. Low NCF1 activity increases the risk for the development of dcSSc and lung fibrosis via expanding profibrotic SPP1+MoMs in a CCL2-dependent manner, contributing to the severity of lung fibrosis in both BLM-treated mice and patients with SSc.

5 February 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SLShu Liu
Shu Liu
QSQi Sun
Qi Sun
QGQingwei Gu
Qingwei Gu
YBYujie Bao
Yujie Bao
WWWei Wang
Wei Wang
XYXinran Yuan
Xinran Yuan
Objective: To determine whether there is a causal relationship between thyroid dysfunction and the risk of age-related cataract (ARC) in the European population.Design: A two-sample Mendelian randomization (MR) study.Methods: Hypothyroidism, hyperthyroidism, free thyroxine (fT4), and thyrotropin (TSH) were selected as exposures. The single nucleotide polymorphisms (SNP) of hypothyroidism and hyperthyroidism were obtained from the genome-wide association studies (GWAS) of the IEU database, including 337,159 subjects. Data for fT4 and TSH (72,167 subjects) were extracted from the ThyroidOmics Consortium. ARC was used as the outcome. The SNPs associated with ARC were selected from a GWAS of 216,362 individuals in the FinnGen database. The main method used was the inverse variance-weighted method, together with four complementary methods. Sensitivity analyses were performed using Cochran’s Q test, MR-PRESSO, MR-Egger regression and leave-one-out test. MR pleiotropy was used to test for pleiotropy. MR Steiger test was used to test for the directionality.Results: Two-sample MR analysis revealed a positive association between genetically predicted hypothyroidism and risk of ARC (OR = 2.501, 95% CI: 1.325-4.720; P = 0.004). Hyperthyroidism, circulating fT4 and TSH levels did not have a significant causal effect on ARC (P > 0.05). The results were robust and reliable, and no horizontal pleiotropy was found after sensitivity analyses. In the MR Steiger test, we found no reverse causal effects of hypothyroidism on the ARC (P <0.001).Conclusions: Our study provides strong evidence that hypothyroidism is a causal determinant of ARC risk.

26 March 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YWYujiao Wang
Yujiao Wang
SGSimin Guo
Simin Guo
YSYirui Shi
Yirui Shi
XWXiaoquan Wei
Xiaoquan Wei
WCWeiwei Chen
Weiwei Chen
LSLingyun Sun
Lingyun Sun

27 November 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
SLShu Liu
Shu Liu
GWGuanhao Wu
Guanhao Wu
MPMengge Pan
Mengge Pan
QSQi Sun
Qi Sun
CGChenjing Gao
Chenjing Gao
LSLingyun Sun
Lingyun Sun
Sjögren’s disease (SjD) is a common systemic autoimmune disease that remains difficult to diagnose early due to non-specific symptoms and lack of definitive biomarkers. This multicentre retrospective cohort study analysed data from 34,958 patients across three hospitals in China to assess the diagnostic potential of routine laboratory tests and to develop a robust, low-cost artificial intelligence model, the Sjögren Multi-criterion Feature Integration Framework (SMFIF). This study is registered with ClinicalTrials.gov (NCT06982482). The model was built using 16 optimal features selected through ensemble learning and SHAP analysis, and validated internally (n = 9329) and externally (n = 545). SMFIF achieved high diagnostic performance, with AUCs of 0.929, 0.934, and 0.964 in testing, internal, and external validation sets, respectively, outperforming conventional biomarkers such as anti-SSA/Ro and ANA. Calibration curves and confusion matrices confirmed its reliability. SMFIF is publicly available and provides probabilities of SjD based on laboratory data, offering a practical diagnostic tool for clinical use.

27 February 2025 in Rheumatology & Autoimmunity
Verified
Journal Article
Open access
XQXiaodong Qin
Xiaodong Qin
YWYujiao Wang
Yujiao Wang
YCYi Chen
Yi Chen
DXDong Xie
Dong Xie
XYXinran Yuan
Xinran Yuan
Background: Tolerogenic dendritic cells (DCs) are promising for cell‐based treatment for systemic lupus erythematosus (SLE). We previously showed that tolerogenic CD1c + DCs play an important role in mesenchymal stem cell transplantation treatment of SLE. We further investigated the immunoregulatory effects of CD141 + DCs on lupus pathogenesis. Methods: A total of 12 SLE patients and 12 age‐ and sex‐matched healthy subjects were included in the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2019 to January 2021. The percentage of peripheral blood CD141 + DCs and their functional expressions of costimulatory markers (CD40, CD80, CD83, and CD86) were compared between patients with SLE and healthy controls. Moreover, the tolerogenic properties of CD141 + and CD1c + DCs were compared following stimulation with lipopolysaccharide (LPS) or SLE serum. Results: Our research revealed that the presence of peripheral CD141 + DCs decreased in SLE patients compared with controls (1.03% ± 0.40% vs. 1.44% ± 0.36%, p < 0.05), which was negatively correlated with the SLE disease activity index score ( R 2 = 0.5547, p = 0.0055). Moreover, CD141 + DCs in patients with SLE exhibited distinct tolerogenic properties by decreasing the mean fluorescence intensity (MFI) of CD40, CD80, and CD86 when compared with controls (2447.00 ± 1386.14 vs. 11,357.25 ± 4581.05, p < 0.001; 1528.00 ± 876.61 vs. 14,181.42 ± 7599.33, p < 0.001; 17,409.42 ± 8180.98 vs. 33,614.25 ± 7408.69, p < 0.001). Furthermore, CD141 + DCs exhibited superior tolerogenicity when compared to CD1c + DCs in SLE, by reducing MFI of CD86 (93,526.58 ± 51,763.00 vs. 169,552.00 ± 51,225.74, p < 0.01 by LPS stimulation; 107,837.40 ± 26,124.76 vs. 145,450.90 ± 50,436.69, p < 0.05 by SLE serum stimulation), and reducing production of tumor necrosis factor α (8.83% ± 3.51% vs. 13.94% ± 2.87%, p < 0.05 by LPS stimulation; 10.12% ± 2.34% vs. 14.39% ± 2.70%, p < 0.05 by SLE serum stimulation). Conclusions: CD141 + DCs play a more significant role than the commonly studied CD1c + DCs in ameliorating immune dysfunction and maintaining immune homeostasis in SLE. Our findings contribute to a better understanding of the immunoregulatory mechanisms underlying SLE and pave the way for novel therapeutic approaches targeting CD141 + DCs.